A pilot study of Campath-1H [alemtuzumab] induction therapy combined with CellCept [mycophenolate mofetil] therapy to allow for a calcineurin inhibitor free regimen after renal transplantation
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Alemtuzumab; Mycophenolate mofetil; Rituximab
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 30 May 2018 Biomarkers information updated
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2012 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.